Roche–Zealand Pharma Peptide Alliance and Pipeline Intelligence

Roche–Zealand Pharma Peptide Alliance and Pipeline Intelligence

Research cutoff: 2026-10-13.

Commercial scope: Exploratory inquiry concerning possible bespoke public-source Roche–Zealand alliance research (F5). No operational transaction-advisory offering, client history, proprietary platform or guaranteed delivery is represented.

1. Executive Hero

The Roche–Zealand collaboration combines a publicly announced territorial licensing structure with development of investigational petrelintide and planned research involving Roche's incretin program. This assessment distinguishes disclosed commercial rights, clinical findings and future milestones to inform evidence-based alliance analysis.

Review Peptide Partnership Strategy

Explore a Possible Alliance Research Scope

2. Strategic Opportunity

Roche's March 2025 announcement describes co-commercialization with Zealand in the United States and Europe, exclusive Roche commercialization elsewhere, and Roche's commercial manufacturing and supply responsibility. Those contractual descriptions must be separated from present-day regulatory approvals and completed manufacturing qualifications. The evolving ZUPREME clinical program supplies a second, independent evidence timeline. Source record: primary document.

3. Business Transformation

The Roche–Zealand relationship illustrates why alliance screening needs two timelines: contractual events and clinical development events. A corporate-development reader can evaluate public territorial rights, Roche's announced manufacturing responsibility and the petrelintide study chronology without treating disclosed obligations as proof of operational completion.

4. Signature Offer — Exploratory Research Discussion Only

A discussion could explore a source-dated rights matrix, alliance-event chronology, public clinical development register or list of diligence questions. These are potential research approaches, not established deliverables. No legal opinion, investment recommendation, transaction valuation or interpretation of confidential agreements is offered.

5. Distinctive Advantage

Roche and Zealand Pharma announced their petrelintide collaboration on March 12, 2025. Zealand Pharma subsequently reported that the agreement became effective on May 9, 2025. Those corporate milestones are distinct from subsequent clinical-trial announcements and results.

6. Credibility Engine

The collaboration announcement, later effectiveness disclosure, registered clinical studies and Phase III program initiation document different events. A partnership announcement establishes disclosed corporate arrangements; it does not, by itself, establish the outcome of clinical studies or authorize petrelintide for patient use.

7. Engagement Experience

An exploratory conversation could define which disclosed agreement provision or study milestone matters to the reader. Any substantive work would require a separately agreed scope and verified capacity; this is not a promise of an active transaction advisory service.

8. Decision Accelerator

Designed for corporate development teams evaluating publicly disclosed peptide alliances or scientific collaboration structures. It cannot establish private contract changes, independently certify a manufacturing site or predict results of the three ZUPREME Phase III studies.

9. Strategic Conversion

Organizations can identify the particular scientific or business question they need answered and request a scoped discussion.

Discuss a Possible Partnership Research Scope

<!-- RESEARCH_BODY_START -->

Independent research body

Related peptide industry research

Global Peptide Industry Intelligence Peptide Transactions and Partnerships Novo Nordisk Pipeline Intelligence

Research inquiry: Contact the editorial team to discuss a possible bespoke research scope. This is an exploratory inquiry, not a promise of an operational service.

Research 1. Relationship and scientific rationale

Roche and Zealand Pharma announced an exclusive collaboration and licensing arrangement on March 12, 2025 concerning petrelintide, a long-acting investigational amylin analogue. Zealand Pharma’s 2025 annual report confirms that the agreement became effective on May 9, 2025 (annual report, note 6.7). Roche also described possible combination development with its dual GLP-1/GIP agonist CT-388, subsequently called enicepatide. This is a corporate development relationship involving scientifically different mechanisms; it should not be confused with evidence that a fixed combination has demonstrated superiority. Public announcements identify the parties and their stated objectives, but do not disclose every contract clause. A responsible alliance review distinguishes what was announced, what was completed, which activities remained prospective and what was confidential. It also distinguishes the scientists' biological hypothesis from later clinical and regulatory outcomes. Each relation needs an exact source date. Source record: primary document.

Research 2. Disclosed geographical rights

Roche's 12 March 2025 announcement states that the companies will co-commercialize petrelintide in the United States and Europe, while Roche will hold exclusive commercialization rights in the rest of the world. It also identifies Roche as responsible for commercial manufacturing and supply. These statements are important to a public-source partnership matrix because territorial rights, development activities and manufacturing responsibilities are different dimensions. They should be reported as the terms publicly described in March 2025, not asserted as full legal findings about an undisclosed final contract. The initial agreement was conditional on closing, but Zealand Pharma’s 2025 annual report confirms an effective date of May 9, 2025 (2025 annual report, note 6.7). Any later amendments or changes to rights still require independent review. Rights in a territory do not establish that the investigational product is approved there or that a commercial supply chain is operating.

Where contractual territorial rights span multiple regions, international patent context and patent-business law research may help frame follow-up legal questions; only the parties’ disclosures and the governing agreements can establish the actual collaboration rights.

Research 3. Petrelintide biology and research status

Roche and Zealand describe petrelintide as an investigational amylin analogue. Treat any claims about tolerability, pharmacology or potential combination benefit as trial-specific and unsupported unless the relevant study results are directly cited.

Research 4. Enicepatide and proposed combination

CT-388, also known as enicepatide, is Roche's investigational dual GLP-1/GIP receptor agonist. The program differs from petrelintide in mechanism and asset identity. Roche's 2026 development materials discussed plans for combination research; a plan does not establish a completed study, demonstrated combined efficacy or regulatory approval. Evidence for two single agents cannot simply be added mathematically to forecast their combined effect. A genuine combination evaluation needs its own population, formulation, intervention dose, comparator, efficacy endpoints and tolerability reporting. An alliance-intelligence matrix should therefore identify standalone petrelintide results separately from CT-388 results and any verified combination-specific trials. That separation is essential when discussing potential scientific complementarity without overstating the evidence. Source record: primary document.

Technology-transfer and collaboration questions may also involve research and innovation intelligence and research-foundation governance, but these external pathways do not substantiate petrelintide or enicepatide efficacy.

Research 5. ZUPREME-1 design and participant counts

ZUPREME-1, NCT06662539, is a randomized, double-blind, placebo-controlled Phase II study of petrelintide in adults with obesity or overweight and relevant conditions without type 2 diabetes. The peer-reviewed ZUPREME-1 report identifies 493 randomized participants and 485 who received at least one dose of study treatment. The primary efficacy analyses included randomized participants who received treatment; the two denominators therefore describe different stages of participation. Original trial publication. The trial investigated several maintenance doses against placebo over 42 weeks, with a primary weight-change analysis at a defined earlier time. Study duration and endpoint timing matter when interpreting percentages. A sponsor description is valuable but a peer-reviewed publication may provide a fuller methods and safety account. Exact populations and endpoint definitions should be reconciled in the publication-stage evidence register. Source record: primary document, primary document. Primary evidence.

Research 6. ZUPREME-1 sponsor findings

Roche announced Phase II ZUPREME-1 topline findings on March 5, 2026 (according to Roche’s sponsor disclosure). It described mean weight loss reaching up to 10.7% at week 42 versus 1.7% for placebo in the reported analysis. Those numbers are source-specific sponsor results, not expected outcomes for an arbitrary individual. The phrase up to must remain tied to the analyzed dose or cohort. A trial conducted without type 2 diabetes does not establish the same effect in a diabetes population. Comparisons with another manufacturer's incretin study are not direct head-to-head comparisons unless supported by a randomized common protocol. The scientific value of the release is that it provides defined evidence for an investigational program, subject to study-method and publication review.

Research 7. Peer-reviewed research and tolerability

The ZUPREME-1 research was published online in The Lancet Diabetes & Endocrinology on September 29, 2026 (DOI: 10.1016/S2213-8587(26)00213-5). A final copy needs the complete paper, exact denominator, estimands, body-weight changes at each time and safety reporting checked against the original. Reports that a publication exists are not sufficient to certify every numerical passage derived from it. The draft deliberately avoids treating a selective press-summary comparison as a complete safety profile. Adverse events need precise denominators, event definitions and follow-up periods. A clinical trial can support further research while leaving important questions unresolved for wider populations, longer exposure, combinations and eventual regulatory assessment. No investigational therapy should be presented as approved merely because a peer-reviewed Phase II paper exists. Primary evidence.

Research inquiry

The evidence categories above help define the specific research boundary relevant to an enterprise decision. A scoped discussion can identify the sources and analytical limitations necessary for that question.

Define Your Peptide Alliance Research Scope

Research 8. ZUPREME-2 distinct diabetes population

ZUPREME-2 is a separate petrelintide Phase II program in participants with overweight or obesity and type 2 diabetes. Zealand Pharma’s March 2026 investor presentation identifies the registered study as NCT06926842, and its official October 2026 newsroom identifies the October 7, 2026 ZUPREME-2 topline announcement. Such evidence, if retained in final copy, must preserve the company-reporting date and exact trial population. The diabetes-focused design is not interchangeable with ZUPREME-1. A measured weight change at a different assessment week cannot be ranked against ZUPREME-1 without explaining population, dose and timing. A full trial publication would support stronger interpretation of clinical results than topline findings alone. Editorially, separate both protocols and specify which source supplies each clinical number. Avoid presenting an early result as final authorization. Source record: primary document.

Research 9. Phase III plans versus initiation

Zealand Pharma announced initiation of the global registrational Phase III ZUPREME program on September 22, 2026, identifying three trials: ZUPREME-3, involving obesity or overweight without type 2 diabetes; ZUPREME-4, involving obesity or overweight with type 2 diabetes; and ZUPREME-5, involving obesity or overweight and established cardiovascular disease. The company described a planned combined enrollment of approximately 7,000 participants. These are company-stated design and planned-enrollment facts, not completed results. Original Zealand Pharma release, September 22, 2026. A program-level announcement differs from an exact ClinicalTrials.gov entry for each individual study and its enrollment status. Dates matter: later trial pages should not be retrospectively treated as registrations that necessarily existed at the earlier research cutoff. The full program needs an explicit matrix of populations, eligibility, trial identifier, study start and last registered update. Phase III initiation is an important corporate and clinical development milestone but not evidence of trial completion, success or future approval. Statements about prospective submission pathways remain company intentions until regulator actions are documented. The website's historical cutoff should be displayed separately from whatever evidence is checked at final release.

Research 10. Manufacturing, patent and legal diligence

The March 2025 alliance disclosure assigns Roche a commercial manufacturing and supply role. That is a contract-related announcement, not documentation that a named facility has passed a current product-specific manufacturing qualification. Supplier research would require exact legal sites, GMP scopes, authorized activities and a separate quality evaluation. Patent and licensing diligence likewise involves more than a public deal description. A press release does not show confidential sublicensing limits, patent-validity analyses, termination clauses or freedom-to-operate opinions. A responsible business analysis can identify likely diligence questions without claiming to have resolved them. Transaction-value figures are allowed under the user-approved narrow V4 exception only if cited directly in a historical research section; this draft chooses not to introduce them. Source record: primary document.

Potential licensing questions should be assessed separately from patent-related corporate law commentary, US technology-law perspectives and corporate and technology-law context. The latter are supplementary reading, not proof of the signed agreement, regulatory standing or freedom to operate.

Original asset A — Disclosed rights and evidence limitations

Source: Roche announcement, 12 March 2025. The agreement subsequently became effective May 9, 2025, as confirmed in Zealand Pharma’s 2025 annual report; later amendments and current operational implementation have not been independently audited.

Original asset B — Chronology by evidence class

In September 2026, Zealand Pharma announced initiation of the registrational Phase III ZUPREME program. The program-level announcement does not demonstrate that every planned participant has been enrolled or that any individual Phase III study has produced results. Trial-specific enrollment and recruitment statements depend on the corresponding dated study records.

The chronology is evidence classification, not a statement that a combination medicine has regulatory approval.

Original corporate filing check (16 October 2026): Zealand Pharma’s 2025 annual report confirms the Roche collaboration became effective in May 2025 and describes the publicly reported geographic rights and Roche’s manufacturing responsibilities. It is evidence of disclosed agreement terms—not present clinical approval, actual facility qualification, or confirmation that undisclosed later amendments do not exist.

Research 11. Strategic analysis and limitations

The Roche–Zealand relationship illustrates how an innovative biotechnology program can be linked with a large pharmaceutical company's scientific and global development resources. That observation does not establish the alliance's ultimate success. Analysts should separate partner capability descriptions, disclosed rights, observed trial outcomes, future planned activity and material uncertainties. A source-dated chronology can distinguish the March 2025 announcement, May 2025 effective date and later 2026 clinical reports. More comprehensive financial, contractual, medical or supplier conclusions require their own specialist evidence. This page is public-source enterprise intelligence, not legal advice, an investment recommendation or personal treatment guidance. Proposed advisory work is conditional on an independently agreed scope and verified delivery process.

Separate legal research and professional insights may be useful for framing diligence questions but do not verify clinical or contractual facts.

Source-checked alliance rights and effective date (editorial correction, October 2026 cutoff)

Zealand Pharma's 2025 Annual Report, note 6.7, identifies F. Hoffmann-La Roche Ltd and Genentech, Inc. as the Roche contracting parties, confirms the collaboration agreement became effective on May 9, 2025, and distinguishes the joint collaboration territory from Roche's exclusive territory. The report identifies a 50/50 sharing of joint development costs, subject to an exception for specified ongoing Zealand Phase IIb studies, and a 50/50 sharing of joint commercialization costs and net profits or losses for collaboration products in the collaboration territory. It states Roche bears commercial manufacturing and supply responsibilities. These are company-reported agreement accounting and rights terms, not evidence of a marketing authorization or independent confirmation that every operational commitment has been performed. Primary source: Zealand Pharma Annual Report 2025, note 6.7.

The same note specifies that Zealand's CT-388 rights concern co-development of a petrelintide–CT-388 combination and do not confer rights to develop CT-388 monotherapy. This distinction must be retained in every alliance-rights matrix and prevents an overbroad claim that Zealand obtained independent rights to Roche's stand-alone incretin asset. No monetary transaction terms are required in this passage, despite the separately authorized narrow financial-research exception.

<!-- RESEARCH_BODY_END -->

Source register

• Roche 12 Mar 2025 original agreement — primary or official record; apply to identified claims only.
• Roche 5 Mar 2026 ZUPREME-1 — primary or official record; apply to identified claims only.
• ZUPREME-1 trial NCT06662539 — primary or official record; apply to identified claims only.
• ZUPREME-2 trial NCT06926842 — primary or official record; apply to identified claims only.

Research and evidence overview